Targeting the interferon beta (IFNβ) pathway promotes a proinflammatory microenvironment [16,17,18], improved adaptive antitumor immune response [19], suppression of cancer stem cells [20,21,22], and is correlated with improved prognosis in TNBC patients [20]. This evidence concerns the gene IFNB1 and cancer.